Company: PSTV
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047698
Chunk: 116

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1A
Chunk 116
---
 our financial results;

•conditions and trends in the markets we currently serve or which we intend to target with our product candidates;

•changes in general economic, industry and market conditions;

•success of competitive products and services;

•changes in market valuations or earnings of our competitors;

•announcements of significant new products, contracts, acquisitions or strategic alliances by us or our competitors;

55 

•our continuing ability to list our securities on an established market or exchange;

•the timing and outcome of regulatory reviews and approvals of our product candidates;

•the commencement or outcome of litigation involving our company, our general industry or both;

•changes in our capital structure, such as future issuances of securities or the incurrence of additional debt;

•actual or expected sales of our common stock by the holders of our common stock; and

•the trading volume of our common stock.

In addition, the financial markets may experience a loss of investor confidence or otherwise experience continued volatility and deterioration. A loss of investor confidence may result in extreme price and volume fluctuations in our common stock that are unrelated or disproportionate to the operating performance of our business, our financial condition or results of operations, which may materially harm the market price of our common stock and result in substantial losses for stockholders. Further, although our common stock is traded on the Nasdaq, there is currently a limited market for our common stock and an active market may never develop. An active trading market in our common stock may not develop.

We may be or become the target of securities litigation, which is costly and time-consuming to defend.

In the past, following periods of market volatility in the price of a company’s securities, the reporting of unfavorable news or continued decline in a company’s stock price, security holders have often instituted class action litigation. The market value of our securities has steadily declined over the past several years for a variety of reasons discussed elsewhere in this “Risk Factors” section, which heightens our litigation risk. If we face such litigation, we could incur substantial legal costs and our management’s attention could be diverted from the operation of our business, causing our business to suffer. Any adverse determination in any such litigation or any amounts paid to settle any such actual or threatened litigation could require that we make significant payments.

We may issue debt and equity securities or securities convertible into equity securities, any of which may be senior to our common stock as to distributions and in liquidation, which could negatively affect the value of our common stock. 

In the future, we may attempt to increase our capital resources by